Hematopoietic stem cells (HSCs) in the bone marrow give rise to all mature B cell types in peripheral lymphoid organs, which provide humoral immunity for protection against foreign pathogens. HSCs first differentiate to lymphoid-primed multipotent progenitors (LMPPs) and common lymphoid progenitors (CLPs), which consist of Ly6D^−^ all-lymphoid progenitors (ALPs) and Ly6D^+^ B cell--biased lymphoid progenitors (BLPs; [@bib27]). BLPs initiate the B cell gene expression program and differentiate via the prepro--B cell stage to pro--B cells, which undergo B lineage commitment ([@bib27]). Pro--B cells subsequently develop via pre--B cells into immature B lymphocytes that emigrate from the bone marrow to the spleen, where they differentiate into distinct mature B cell types ([@bib23]; [@bib2]).

The entry of lymphoid progenitors into the B cell pathway depends on several transcription factors, including the helix-loop-helix protein E2A, the early B cell factor EBF1, and the paired domain transcription factor Pax5 ([@bib46]; [@bib40]). These three regulators act in the genetic hierarchy E2A→EBF1→Pax5, as early B cell development is sequentially arrested at the ALP, prepro--B cell, or earliest pro--B cell stage in the absence of E2A, EBF1, and Pax5, respectively ([@bib4]; [@bib34]; [@bib47]; [@bib27]). Moreover, the transcription factor E2A directly activates the *Ebf1* gene by binding to the distal *Ebf1* promoter ([@bib67]; [@bib58]), which results in the initiation of *Ebf1* expression at the CLP stage ([@bib77]; [@bib27]). EBF1 in turn binds to and activates the *Pax5* promoter region ([@bib15]), which gives rise to maximal *Pax5* expression in pro--B cells ([@bib18]). Finally, Pax5 further increases *Ebf1* expression through a positive feedback loop by binding to the proximal *Ebf1* promoter ([@bib19]; [@bib58]), which leads to completion of the B cell commitment process in pro--B cells ([@bib40]).

At the molecular level, EBF1 is known to collaborate with E2A in the activation of B cell--specific genes, such as the surrogate light chain genes *Igll* (λ5) and *Vpreb1* ([@bib65]; [@bib48]). Consistent with this finding, B cell--specific genes are not activated at the CLP stage in *Ebf1* mutant mice ([@bib77]). EBF1 also represses B lineage--inappropriate genes, which may restrict the developmental options of lymphoid progenitors to the B cell lineage ([@bib53]), similar to the B cell commitment factor Pax5 ([@bib40]). EBF1 controls gene activity as an epigenetic regulator, as it can induce DNA demethylation, nucleosome remodeling, and active chromatin modifications at its target genes ([@bib37]; [@bib15]; [@bib73]). Genome-wide analyses have recently identified a large spectrum of regulated EBF1 target genes in pro--B cells, which revealed an important role for EBF1 in pre--B cell receptor (pre--BCR) and phosphoinositide 3-kinase (PI3K) signaling, as well as in cell adhesion and migration during early B lymphopoiesis ([@bib35]; [@bib73]). Hence, the function of EBF1 at the onset of B cell development has been fairly well characterized. EBF1 is expressed throughout B lymphopoiesis from the pro--B to the mature B cell stage ([@bib20]). However, nothing is yet known about the role of EBF1 in late B cell development.

Here, we have performed conditional loss-of-function experiments to demonstrate that EBF1 is essential for the generation of all mature B cell types. Marginal zone (MZ) and B-1 B cells were lost upon conditional *Ebf1* inactivation, whereas follicular (FO) and germinal center (GC) B cells were generated in reduced numbers, but tolerated the loss of EBF1 for some time. EBF1 was, however, required for the maintenance of GC B cells during an immune response as well as for intracellular calcium signaling, proliferation, and survival of activated FO B cells in response to BCR stimulation. Genome-wide ChIP- and RNA-sequencing of FO B cells identified activated EBF1 target genes and indirectly EBF1-regulated genes that code for cell surface receptors, intracellular signal transducers and transcription factors implicated in different B cell signaling pathways. Notably, gain-of-function experiments revealed that ectopic *Ebf1* expression from the *Rosa26* locus efficiently induced the development of bona fide B-1 cells at the expense of MZ, FO, and GC B cells. Together, these data identified novel important roles of EBF1 in the generation, maintenance, and function of distinct mature B cell types.

RESULTS
=======

Nonredundant in vivo functions of EBF1 and Pax5 at the onset of B cell development
----------------------------------------------------------------------------------

To investigate the lymphoid expression of *Ebf1* at the single-cell level, we generated an *Ebf1*^ihCd2^ allele by inserting an internal ribosome entry sequence (IRES)-*hCd2* (ihCd2) reporter gene into the 3′ untranslated region of the *Ebf1* gene, which resulted in normal B cell development of *Ebf1*^ihCd2/ihCd2^ mice ([Fig. S1](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp1} and unpublished data). As shown by flow cytometric analysis of *Ebf1*^ihCd2/+^ mice ([Fig. 1 A](#fig1){ref-type="fig"}), *Ebf1* expression is weakly activated in ALPs, increases in BLPs and prepro--B cells, remains high in pro--B, pre--B, and immature B cells of the bone marrow, is moderately down-regulated in FO, MZ, B-1, and GC B cells of the spleen, and is subsequently lost in terminally differentiated plasma cells of the bone marrow. Furthermore, *Ebf1* is not expressed in other hematopoietic lineages, as exemplified for T cells ([Fig. 1 A](#fig1){ref-type="fig"} and unpublished data). Semiquantitative immunoblot analysis revealed a threefold lower expression of the EBF1 protein in FO B cells compared with pro--B cells ([Fig. 1 B](#fig1){ref-type="fig"}), which is consistent with the moderate down-regulation of expression of the *Ebf1*^ihCd2^ allele that is observed in all mature B cell types ([Fig. 1 A](#fig1){ref-type="fig"}).

![**Nonredundant functions of EBF1 and Pax5 in early B cell development.** (A) *Ebf1*^ihCd2/+^ (blue) and WT (black line) mice were analyzed by flow cytometry for human (h) CD2 expression in different progenitors, B cell types, and T cells, which were defined as described in Materials and methods. (B) Expression of EBF1 protein in cultured pro--B cells and MACS-sorted FO B cells from lymph nodes. One of two immunoblot experiments is shown. Numbers indicate the relative proportion of nuclear extracts analyzed. The EBF1 protein abundance is normalized to expression of the TBP, and the size (kilodaltons) of the two proteins is indicated to the left. (C and D) B cell development in *Vav*-Cre *Ebf1*^fl/−^ mice with or without ectopic Pax5 expression from the *Ikzf1*^Pax5^ allele. Progenitor and B cell types were investigated by flow cytometry of bone marrow cells isolated from mice of the indicated genotypes. The relative percentage of each cell type is indicated in the respective quadrant, and the gating is shown above the FACS plot. The different cell types were defined as described in Materials and methods. (E and F) B cell development in *Vav*-Cre *Pax5*^fl/fl^ mice with or without ectopic EBF1 expression from the *R26CA*^Ebf1^ allele (E). GFP expression, indicating EBF1 expression, in Pax5-deficient progenitors of *Vav*-Cre *R26CA*^Ebf1/+^ *Pax5*^fl/fl^ mice (F). Number of mice of each genotype analyzed: *n* = 8 (C); *n* = 5 (D); and *n* = 3 (E).](JEM_20112422R_Fig1){#fig1}

To study the function of *Ebf1* throughout B cell development, we generated a floxed (fl) *Ebf1* allele, which resulted in Cre-mediated deletion of the last 429 codons of the *Ebf1* gene and subsequent expression of an EBF1-GFP fusion protein from the deleted *Ebf1*^Δ^ allele ([Fig. S2, A--C](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp2}). Surprisingly, however, *Ebf1*^Δ/+^ mice expressed GFP at a significant level only in pro--B cells, but not at later developmental stages (Fig. S2 D), suggesting that the presence of the N-terminal 148 aa of EBF1 appeared to destabilize the GFP fusion protein. Importantly, B cell development was normal in homozygous *Ebf1*^fl/fl^ mice, indicating that the floxed *Ebf1* allele provided WT EBF1 function (unpublished data). Pan-hematopoietic deletion of the floxed *Ebf1* allele with the *Vav*-Cre transgene ([@bib14]) did not affect the differentiation of HSCs to ALPs and BLPs, but resulted in a stringent differentiation arrest at the prepro--B cell stage in *Vav*-Cre *Ebf1*^fl/--^ mice ([Fig. 1 C](#fig1){ref-type="fig"}), which therefore recapitulated the early developmental block of *Ebf1^−/−^* mice ([@bib34]).

Although *Ebf1* is upstream of *Pax5* in the genetic hierarchy of B cell development ([@bib40]), the loss of either transcription factor results in a similar block at the transition to the committed pro--B cell stage in adult mice ([@bib34]; [@bib47]). The question therefore arises whether EBF1 and Pax5 fulfill different or largely redundant functions during B cell commitment. This issue has been addressed by retroviral rescue experiments using in vitro cultured progenitors, which demonstrated that ectopic Pax5 expression could not rescue the EBF1 deficiency ([@bib39]) and that retroviral EBF1 expression was unable to overcome the *Pax5* mutant developmental arrest ([@bib53]). In a similar situation, however, retroviral Pax5 expression in E2A (*Tcf3*)-deficient progenitors failed to rescue pro--B cell development in vitro ([@bib63]), and yet transgenic Pax5 expression under the control of the *Ikaros* (*Ikzf1*) locus from the *Ikzf1*^Pax5^ allele ([@bib69]) restored pro--B cell development in vivo in the bone marrow of *Vav*-Cre *Tcf3*^fl/fl^ *Ikzf1*^Pax5/+^ mice ([@bib33]). As shown by flow cytometric analysis ([Fig. 1 D](#fig1){ref-type="fig"}), B cell development was still arrested at the prepro--B cells in the bone marrow of *Vav*-Cre *Ebf1*^fl/--^ *Ikzf1*^Pax5/+^ mice like in control *Vav*-Cre *Ebf1*^fl/--^ mice, demonstrating that ectopic Pax5 expression in vivo is unable to compensate for the loss of EBF1 in early B cell development.

To perform the reciprocal experiment, we inserted a C-terminally tagged *Ebf1* minigene into the ubiquitously expressed *Rosa26* (*R26*) locus between upstream sequences consisting of a *C*MV enhancer-*a*ctin promoter (CA) region and floxed Neo-Stop cassette and a downstream region containing an IRES-*Gfp* gene and polyadenylation signal ([Fig. S3, A and B](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp3}). Upon Cre-mediated excision of the Neo-Stop cassette, the CA promoter drives expression of both EBF1 and GFP from the *R26CA*^Ebf1/+^ allele (Fig. S3, C and D). As shown by flow cytometric analysis ([Fig. 1 E](#fig1){ref-type="fig"}), B cell development was still arrested at the same c-Kit^hi^ (pre)pro--B cell stage in *Vav*-Cre *Pax5*^fl/fl^ *R26CA*^Ebf1/+^ mice as in *Vav*-Cre *Pax5*^fl/fl^ littermates. However, the *R26CA*^Ebf1^ allele gave rise to GFP, and thus EBF1 expression in *Vav*-Cre *Pax5*^fl/fl^ *R26CA*^Ebf1/+^ (pre)pro--B cells ([Fig. 1 F](#fig1){ref-type="fig"}) and could overcome the *Ebf1* mutant differentiation arrest by promoting pro--B cell development in *Vav*-Cre *Ebf1*^fl/--^ *R26CA*^Ebf1/+^ mice (Fig. S3 C). We therefore conclude that ectopic EBF1 expression from the *Rosa26* locus is unable to rescue the Pax5 deficiency in early B cell development. Together, these data indicate that Pax5 and EBF1 fulfill nonredundant in vivo functions during B cell commitment.

Essential function of EBF1 in early B cell development
------------------------------------------------------

To investigate the role of EBF1 during B lymphopoiesis, we used the *Cd79a*-Cre and *Cd23*-Cre lines to delete the floxed *Ebf1* allele of control *Ebf1*^fl/+^ and experimental *Ebf1*^fl/--^ littermates at different stages of B cell development. This experimental strategy was validated by our observation that similar numbers of all B cell subtypes were present in the bone marrow and spleen of heterozygous *Ebf1*^+/−^ mice compared with WT mice (unpublished data). The *Cd79a*-Cre line (also known as *mb1*-Cre line; [@bib24]) initiates gene deletion at the transition from prepro--B to committed pro--B cells ([@bib33]), and was thus used to study the effect of EBF1 in early B cell development ([Fig. 2](#fig2){ref-type="fig"}). Pro--B cells (CD19^+^c-Kit^+^) were fourfold reduced in the bone marrow of *Cd79a*-Cre *Ebf1*^fl/--^ mice compared with control *Cd79a*-Cre *Ebf1*^fl/+^ littermates ([Fig. 2, A and B](#fig2){ref-type="fig"}). PCR genotyping and GFP expression demonstrated that about half of the remaining pro--B cells in *Cd79a*-Cre *Ebf1*^fl/--^ mice had undergone *Ebf1* deletion in contrast to complete deletion in all pro--B cells of control littermates. Hence, pro--B cells do not tolerate the loss of EBF1 and thus stringently depend on this transcription factor ([Fig. 2 C](#fig2){ref-type="fig"}). Pre--B cells (CD19^+^CD25^+^) were decreased by 28-fold in *Cd79a*-Cre *Ebf1*^fl/--^ mice and contained only the undeleted floxed allele contrary to control *Cd79a*-Cre *Ebf1*^fl/+^ littermates ([Fig. 2, A--C](#fig2){ref-type="fig"}). Consequently, only pro--B cells without *Ebf1* deletion could differentiate to pre--B cells, indicating that EBF1 is required for the pro--B to pre--B cell transition.

![**Function of EBF1 in early B cell development.** (A and B) Relative percentages (A) and absolute numbers (B) of pro--B and pre--B cells were determined by flow cytometric analysis of bone marrow from *Cd79a*-Cre *Ebf1*^fl/+^ mice (gray bars; fl/+) and *Cd79a*-Cre *Ebf1*^fl/−^ littermates (black bars; fl/−). *n*, number of mice analyzed. Statistical data (B) are shown with SEM and were analyzed by Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01. (C) Deletion of the floxed *Ebf1* allele in pro--B and pre--B cells was analyzed by PCR and GFP expression. The PCR fragments corresponding to the deleted (Δ) or intact (fl) floxed allele are indicated to the right and their size (base pairs) to the left of the gel.](JEM_20112422_Fig2){#fig2}

Role of EBF1 in the generation of all mature B cell types
---------------------------------------------------------

As the *Cd23*-Cre line initiates Cre-mediated deletion in immature B cells and leads to efficient deletion in MZ and FO B cells of the spleen ([@bib33]), we used this Cre line to study the role of EBF1 in late B cell development. Total B cells were consistently reduced by 40% in the spleen of *Cd23*-Cre *Ebf1*^fl/--^ mice compared with control *Cd23*-Cre *Ebf1*^fl/+^ littermates at 8 and 16 wk of age ([Fig. 3, A and B](#fig3){ref-type="fig"}). FO B cells of *Cd23*-Cre *Ebf1*^fl/--^ mice were similarly decreased ([Fig. 3, A and B](#fig3){ref-type="fig"}), underwent full deletion of the floxed *Ebf1* allele ([Fig. 3 C](#fig3){ref-type="fig"}), and, as a result, lost most of their EBF1 protein compared to control FO B cells, as shown by semiquantitative immunoblot analysis of CD23^+^ splenic B cells ([Fig. 3 D](#fig3){ref-type="fig"}). Hence, FO B cells seem to tolerate the loss of EBF1 for quite some time. Competitive bone marrow reconstitution experiments revealed, however, that the development of EBF1-deficient FO B cells of the *Cd23*-Cre *Ebf1*^fl/fl^ genotype was more strongly impaired in the presence of competing WT FO B cells (unpublished data). Notably, EBF1-deficient FO B cells significantly down-regulated only the expression of the surface protein CD21 ([Fig. 3 E](#fig3){ref-type="fig"} and not depicted) in contrast to the radical change of cell surface phenotype observed in Pax5-deficient FO B cells ([@bib25]). Consistent with this notion, the Pax5 protein is normally expressed in EBF1-deficient FO B cells ([Fig. 3 D](#fig3){ref-type="fig"}), demonstrating that *Pax5* expression is no longer under the control of EBF in late B cell development.

![**Role of EBF1 in late B lymphopoiesis.** (A and B) Relative percentages and absolute numbers of B-1, MZ, and FO B cells were analyzed by flow cytometry of the spleen from *Cd23*-Cre *Ebf1*^fl/+^ mice (gray bars) and *Cd23*-Cre *Ebf1*^fl/−^ littermates (black bars) at the age of 8 (A) and 16 (B) weeks. *n*, number of mice analyzed. Statistical data are shown with SEM and were analyzed by the Student's *t* test. \*\*, P \< 0.01; \*\*\*, P \< 0.001. (C) PCR genotyping of sorted FO, MZ, and B1 B cells of the indicated genotypes. The size (base pairs) and identity of the PCR fragments is shown to the left and right of the gel, respectively. C, genomic *Ebf1*^fl/fl^ or *Ebf1*^fl/Δ^ control DNA. (D) CD23^+^ splenic B cells of the indicated genotypes were isolated by MACS sorting before immunoblot analysis of serially diluted nuclear extracts (indicated by wedges) with EBF1, TBP, and Pax5 antibodies. The size (kilodaltons) of the proteins is indicated to the left. One of two immunoblots is shown. (E) Flow cytometric analysis of the cell surface phenotype of mature B cells (IgM^lo^IgD^hi^) from the spleen of *Cd23*-Cre *Ebf1*^fl/+^ mice (gray) and *Cd23*-Cre *Ebf1*^fl/−^ littermates (black line). (F) Analysis of MZ B cells as CD1d^hi^CD21^hi^ splenic B cells in 8-mo-old *Cd23*-Cre *Ebf1*^fl/−^ and control *Cd23*-Cre *Ebf1*^fl/+^ littermates.](JEM_20112422_Fig3){#fig3}

In comparison to FO B cells, the MZ and B-1 B cells of the spleen were more strongly (2.5--4 fold) reduced in *Cd23*-Cre *Ebf1*^fl/--^ mice relative to control *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 3, A, B and F](#fig3){ref-type="fig"}). In this context, it is important to note that the CD19^+^B220^lo/--^ B-1 cells of the spleen exhibited the classical B-1 cell surface phenotype, including no or low expression of CD23 (see below). Our observation that the *Cd23*-Cre line gave rise to the loss of CD23^lo/--^ B-1 cells in *Cd23*-Cre *Ebf1*^fl/--^ mice indicates that B-1 cells also develop from transitional CD23^+^ B cells similar to MZ B cells. Interestingly, the floxed *Ebf1* allele was not deleted in the residual MZ and B-1 B cells of *Cd23*-Cre *Ebf1*^fl/--^ mice in contrast to control littermates ([Fig. 3 C](#fig3){ref-type="fig"}). These data therefore demonstrated that the differentiation of MZ and B-1 B cells stringently depends on EBF1 in contrast to FO B cells.

EBF1-dependent maintenance of GC B cell development
---------------------------------------------------

We next immunized *Cd23*-Cre *Ebf1*^fl/--^ and control *Cd23*-Cre *Ebf1*^fl/+^ mice with sheep red blood cells (SRBCs) to study the role of EBF1 in the development of GC B cells at day 7 after immunization ([Fig. 4, A--E](#fig4){ref-type="fig"}). As shown by flow cytometry, the number of GC B cells was 4.5-fold reduced in the spleen of *Cd23*-Cre *Ebf1*^fl/--^ mice compared with control littermates ([Fig. 4, A and B](#fig4){ref-type="fig"}). Although most GC B cells of *Cd23*-Cre *Ebf1*^fl/--^ mice efficiently deleted the floxed *Ebf1* allele ([Fig. 4 C](#fig4){ref-type="fig"}), they behaved like control GC B cells as they down-regulated CD23 and CD38 expression and normally proliferated as shown by their increased cell size ([Fig. 4 D](#fig4){ref-type="fig"}). Moreover, the loss of EBF1 only minimally affected class switch recombination to IgG1 and had no effect on switching to IgG3, as GC B cells expressing IgG1 (9.5×) and IgG3 (4×) were similarly reduced like total GC B cells (4.5×; [Fig. 4 B](#fig4){ref-type="fig"}). Histological analysis revealed that GCs with PNA^+^ GC B cells (brown) were present in similar numbers but had a significantly reduced size in the spleen of *Cd23*-Cre *Ebf1*^fl/--^ mice relative to control *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 4 E](#fig4){ref-type="fig"}). At day 14 after SRBC immunization, GC B cells were 10-fold and thus more severely reduced ([Fig. 4, F and G](#fig4){ref-type="fig"}). Moreover, only rare GCs of small size could be detected by histological analysis in the spleen of *Cd23*-Cre *Ebf1*^fl/--^ mice compared with control *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 3 H](#fig3){ref-type="fig"}). We conclude therefore that EBF1 is required for the maintenance, but not initiation of GC B cell development.

![**Impaired maintenance of GC B cells in the absence of EBF1.** (A and B) The abundance and immunoglobulin class switching of splenic GC B cells were determined by flow cytometry as relative percentages (A) and absolute cell numbers (B). 7 d after immunization of *Cd23*-Cre *Ebf1*^fl/+^ mice (gray bars) and *Cd23*-Cre *Ebf1*^fl/−^ mice (black bars) with SRBCs. *n*, number of mice analyzed. (C) PCR genotyping of sorted GC B cells 7 d after immunization with SRBCs. The size (base pairs) and identity of the PCR fragments is shown to the left and right of the gel, respectively. C, genomic *Ebf1*^fl/Δ^ control DNA. (D) Characterization of EBF1-deficient GC B cells. Splenic GC B cells (PNA^+^Fas^+^B220^+^CD19^+^; gray) of *Cd23*-Cre *Ebf1*^fl/+^ and *Cd23*-Cre *Ebf1*^fl/--^ mice were analyzed for their cell size and expression of CD23 and CD38 at day 7 after immunization with SRBCs. Non--B cells (B220^--^CD19^--^; dashed line) and FO B cells (CD19^+^CD21^int^CD23^hi^; black line) served as controls. (E) Size of GCs in the spleen of *Cd23*-Cre *Ebf1*^fl/−^ and *Cd23*-Cre *Ebf1*^fl/+^ mice at day 7 after immunization with SRBCs. Cryosections of the spleen were stained for peanut agglutinin (PNA, brown) and IgD (blue) expression as described in Materials and methods. The black scale bar corresponds to 500 µm. (F--H) GC B cells in the spleen of *Cd23*-Cre *Ebf1*^fl/−^ mice and control *Cd23*-Cre *Ebf1*^fl/+^ littermates at day 14 after immunization with SRBCs, as shown by flow cytometry (F and G) and histological analysis (H). Statistical data (B and G) are shown with SEM and were analyzed by Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; and \*\*\*\*, P \< 0.0001.](JEM_20112422R_Fig4){#fig4}

We next investigated the immune response to the T cell--dependent antigen 4-hydroxy-3-nitrophenylacetyl-conjugated keyhole limpet hemocyanin at day 14 after immunization ([Fig. 5](#fig5){ref-type="fig"}). GC B cells were eightfold decreased and IgG1^+^ GC B cells were reduced by 33-fold in the spleen of *Cd23*-Cre *Ebf1*^fl/--^ mice compared with control *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 5, A and B](#fig5){ref-type="fig"}) consistent with the identification of very few GCs of small size by immunohistochemical analysis ([Fig. 5 C](#fig5){ref-type="fig"}). Moreover, very little anti--NP-IgG1 antibody-secreting cells (ASCs) could be detected by ELISPOT assay in the spleen and bone marrow of *Cd23*-Cre *Ebf1*^fl/--^ mice in contrast to control *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 5 D](#fig5){ref-type="fig"}). Analysis of serum antibody titers by ELISA additionally revealed that high-affinity and total anti--NP-specific IgG1 antibodies were reduced by 14- and 7.5-fold, respectively, in *Cd23*-Cre *Ebf1*^fl/--^ mice relative to *Cd23*-Cre *Ebf1*^fl/+^ littermates ([Fig. 5 E](#fig5){ref-type="fig"}). Together these data demonstrate that EBF1 is required for maintaining the GC B cell and plasma cell responses to foreign antigens.

![**Impaired immune responses in the absence of EBF1.** (A--E) NP-specific immune responses at day 14. *Cd23*-Cre *Ebf1*^fl/+^ mice (fl/+; gray bars) and *Cd23*-Cre *Ebf1*^fl/--^ littermates (fl/−; black bars) were immunized with 4-hydroxy-3-nitrophenylacetyl-conjugated keyhole limpet hemocyanin (in Alum) and analyzed after 14 d by flow cytometric analysis of splenic B cells (A and B), immunohistochemical staining of the spleen (C), ELISpot assay (D), and ELISA (E). (D) The total number of anti--NP-IgG1 ASCs in the spleen or bone marrow (femur and tibia of the two hind legs) was determined by ELISpot assay using NP~4~-BSA-- or NP~23~-BSA--coated plates for detecting cells secreting high-affinity or total anti--NP-IgG1 antibodies, respectively. (E) The serum titers of anti--NP-specific IgG1 antibodies were analyzed by ELISA using NP~4~-BSA-- or NP~23~-BSA--coated plates for detecting high-affinity or total IgG1 antibodies, respectively. Bars, 500 µm. *n*, number of mice analyzed. Statistical data (B and D) are shown with SEM and were analyzed by Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20112422_Fig5){#fig5}

EBF1-dependent survival and proliferation of FO B cells in response to BCR signaling
------------------------------------------------------------------------------------

To investigate the role of EBF1 in BCR signaling, we purified splenic B cells from *Cd23*-Cre *Ebf1*^fl/--^ and control *Cd23*-Cre *Ebf1*^fl/+^ mice to measure intracellular calcium mobilization in response to stimulation with anti-IgM antibodies. Intracellular calcium signaling was strongly impaired in *Cd23*-Cre *Ebf1*^fl/--^ B cells in contrast to control *Cd23*-Cre *Ebf1*^fl/+^ B cells ([Fig. 6 A](#fig6){ref-type="fig"}), indicating that the loss of EBF1 results in a severe BCR signaling defect. We next performed a time-course analysis of anti-IgM stimulation with FO B cells, which were purified from lymph nodes by T cell depletion. *Cd23*-Cre *Ebf1*^fl/--^ FO B cells were already preferentially lost at 12 h after BCR stimulation, and the remaining cells contained an increasingly larger fraction of Annexin V--positive cells, reaching 83% of all FO B cells after 48 h, in contrast to control *Cd23*-Cre *Ebf1*^fl/+^ B cells ([Fig. 6 B](#fig6){ref-type="fig"}). As signaling through the transmembrane protein tyrosine phosphatase CD45 cooperates with BCR stimulation in controlling cell survival ([@bib26]), we repeated the time-course analysis with FO B cells of the same genotypes, which were this time positively selected by MACS sorting with anti-B220 beads. The number of *Cd23*-Cre *Ebf1*^fl/--^ B cells significantly increased and Annexin V^+^ cells decreased at all time points of BCR stimulation as a result of continuous activation of the CD45 isoform B220 by the presence of anti-B220 beads ([Fig. 6 B](#fig6){ref-type="fig"}). Hence, CD45 signaling does not depend on EBF1, and can thus partially rescue the survival defect of EBF1-deficient FO B cells in response to BCR stimulation. Finally, we labeled B220-sorted FO B cells with the CellTrace Violet reagent to study their proliferation in response to stimulation with anti-IgM and IL-4 for 4 d. As revealed by the dilution of the CellTrace Violet dye, 30% of the control *Cd23*-Cre *Ebf1*^fl/+^ B cells proliferated under these conditions in contrast to 3% of the *Cd23*-Cre *Ebf1*^fl/--^ B cells ([Fig. 6 C](#fig6){ref-type="fig"}). These data therefore revealed an essential role of EBF1 in the regulation of B cell survival and proliferation in response to BCR signaling.

![**B cell signaling defects in the absence of EBF1.** (A) FO B cells were purified from the spleen of *Cd23*-Cre *Ebf1*^fl/+^ mice (black line; *n* = 2) and *Cd23*-Cre *Ebf1*^fl/--^ mice (red line; *n* = 4) by MACS depletion of non--B cells with anti-PE beads after staining with PE-labeled TCRβ, CD4, CD8a, Mac1, and DX5 (Lin) antibodies. Intracellular Ca^2+^ fluxes were recorded as the fluorescence 405/485 nm ratio of Indo-1 emission after addition of anti-IgM antibody (arrow). (B) Partial rescue of activated EBF1-deficient B cells from apoptosis by CD45 stimulation. FO B cells from lymph nodes of *Cd23*-Cre *Ebf1*^fl/--^ mice (open triangle and gray surface; *n* = 4) and *Cd23*-Cre *Ebf1*^fl/+^ littermates (black square and line; *n* = 4) were purified by MACS depletion of T cells with anti-PE beads after staining with PE-labeled TCRβ, CD4, and CD8a antibodies or were positively selected with anti-B220 MACS beads. The number of B cells and their Annexin V staining were determined by flow cytometry by gating on live cells at the indicated time points after anti-IgM stimulation. (C) FO B cells from lymph nodes of the indicated genotypes were positively selected with anti-B220 MACS beads and stained with CellTrace Violet reagent before stimulation with anti-IgM and IL-4 or with anti-CD40 and IL-4 for 4 d. The relative percentages of proliferating and IgG1^+^ B cells were determined by flow cytometric analysis. *n* = 3 (both genotypes) for anti-IgM plus IL-4 stimulation; *n* = 8 (*Cd23*-Cre *Ebf1*^fl/+^) and *n* = 10 (*Cd23*-Cre *Ebf1*^fl/--^) for anti-CD40 plus IL-4 stimulation. (D) FO B cells were purified from lymph nodes of *Cd23*-Cre *Ebf1*^fl/--^ and *Cd23*-Cre *Ebf1*^fl/+^ mice, as described in B, before stimulation with anti-CD40 and IL-4 for up to 4 d. The number and Annexin V staining of live B cells were determined by flow cytometry. *n* = 4 for each genotype. (E) PCR genotyping of T cell--depleted B cells from lymph nodes of the indicated genotypes after 4 d of anti-CD40 plus IL-4 stimulation. C, genomic *Ebf1*^fl/Δ^ control DNA.](JEM_20112422Rr_Fig6){#fig6}

Similar to BCR stimulation, treatment with anti-CD40 and IL-4 resulted in increased apoptosis of T cell--depleted FO B cells from the lymph nodes of *Cd23*-Cre *Ebf1*^fl/--^ mice, whereas positive selection and stimulation with anti-B220 beads largely rescued the survival defect of EBF1-deficient FO B cells compared with control *Cd23*-Cre *Ebf1*^fl/+^ B cells ([Fig. 6, D and E](#fig6){ref-type="fig"}). In contrast to BCR signaling, the B220-sorted FO B cells from *Cd23*-Cre *Ebf1*^fl/--^ mice efficiently proliferated upon anti-CD40 plus IL-4 treatment and underwent class switch recombination to IgG1 at a similar frequency compared with control *Cd23*-Cre *Ebf1*^fl/+^ FO B cells ([Fig. 6 C](#fig6){ref-type="fig"}). We conclude therefore that EBF1 plays no or only a minimal role in controlling B cell proliferation and IgG1 class switch recombination in response to CD40 and IL-4 signaling.

EBF1 regulates genes involved in different signaling pathways of FO B cells
---------------------------------------------------------------------------

To gain insight into the molecular function of EBF1 in mature B cells, we next determined the genomic binding pattern and target genes of EBF1 in FO B cells, which were purified from lymph nodes of WT C57BL/6 mice by MACS depletion of non-B cells. The purified FO B cells were analyzed by chromatin immunoprecipitation (ChIP) with an EBF1 antibody combined with deep sequencing (ChIP-seq). Using a p-value of \<10^−10^ for peak calling, we identified only 281 EBF1 peaks in FO B cells ([Fig. 7, A and B](#fig7){ref-type="fig"}; [Table S1](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp4}). Importantly, the EBF1 consensus recognition sequence was present in 95% of all EBF1 peaks ([Fig. S4 A](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp5}), which defined 247 EBF1 target genes in FO B cells ([Fig. 7 C](#fig7){ref-type="fig"} and Fig. S4 B). In contrast, ChIP-sequencing with the same EBF1 antibody detected 5,430 EBF1 peaks corresponding to 3,321 EBF1 target genes in *Rag2*^−/−^ pro--B cells ([Fig. 7, A-C](#fig7){ref-type="fig"}; and Fig. S4 B). These numbers are similar to the 5,071 EBF1 peaks and 3,138 EBF1 target genes that were recently identified by ChIP-sequencing of A-MuLV-transformed pro--B cells ([@bib73]). Interestingly, 91% of all EBF1 peaks in FO B cells are already present in pro--B cells, thus defining 230 common EBF1 target genes ([Fig. 7, B and C](#fig7){ref-type="fig"}). In summary, our ChIP-sequencing data revealed few EBF1 peaks and target genes in FO B cells.

![**Genome-wide analysis of regulated EBF1 target genes in FO B cells.** (A) EBF1 binding at the *Hck* locus. EBF1-binding sites were identified by ChIP-sequencing in short-term cultured *Rag2*^−/−^ pro--B cells and mature FO B cells, which were MACS-sorted from lymph nodes of WT C57BL/6 mice. DNase I hypersensitive (DHS) sites of FO B cells are additionally shown together with the exon--intron structure of the *Hck* gene and a scale bar indicated in kilobases. (B and C) Identification of EBF1 peaks and target genes in FO B cells compared with pro--B cells. EBF1 peaks (B) were identified by peak calling using a p-value of \<10^−10^ and were assigned to target genes (C), if they were located from −50 kb upstream of the transcription start site (TSS) to +50 kb downstream of the transcription end site (TES). A second ChIP-seq experiment ([Table S2](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp6}) yielded similar results. (D) Identification of *Ell3* and *Scd1* as EBF1-activated genes in FO B cells by RNA-sequencing of polyA^+^ RNA from WT and *Cd23*-Cre *Ebf1*^fl/−^ (*Ebf1*^Δ/−^) FO B cells (sorting strategy in [Fig. S5, A and C](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp7}). (E) Scatter plot of gene expression differences observed between WT and *Ebf1*^Δ/−^ FO B cells. The normalized expression values of each gene in the two B cell types were plotted as reads per gene per million mapped sequence reads (RPM). Genes are highlighted in blue or red color, if they were expressed \>10 RPMs and regulated at least fourfold between the two cell types. The data of one RNA-sequencing experiment for each cell type was analyzed (Table S2). (F--H) Expression of activated EBF1 target genes (F), as well as indirectly EBF1-activated (G) and EBF1-repressed (H) genes. The expression of each gene in WT (gray bar) and *Ebf1*^Δ/−^ (black bar) FO B cells is shown as normalized expression value, which was determined as reads per kilobase of exon per million mapped sequence reads (RPKM). Different colors indicated genes of distinct functional categories.](JEM_20112422_Fig7){#fig7}

We next investigated to what extent these EBF1 target genes depend on EBF1 for their expression in FO B cells. To this end, we used RNA-sequencing to determine and compare the gene expression level of each gene in FO B cells isolated from the spleen of WT and *Cd23*-Cre *Ebf1*^fl/--^ (*Ebf1*^Δ/--^) mice ([Fig. S5, A and C](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp8}), as exemplified for the EBF1-activated genes *Ell3* and *Scd1* ([Fig. 7 D](#fig7){ref-type="fig"}). Scatter plot analysis of normalized expression values (RPM) of all genes in WT and *Ebf1* mutant FO B cells demonstrated that the transcription of most genes (indicated in black) was not or was only minimally affected in the absence of EBF1 ([Fig. 7 E](#fig7){ref-type="fig"}). A small number (35) of genes were more than fourfold activated (blue), and even fewer genes (19) were similarly repressed (red) by EBF1 in WT FO B cells compared with *Ebf1*^Δ/--^ FO B cells ([Fig. 7 E](#fig7){ref-type="fig"}). When we also considered EBF1 binding at the regulated genes, we identified only 10 activated EBF1 target genes that were more than threefold activated by EBF1 and were additionally expressed at a level of \>10 RPKM in WT FO B cells ([Fig. 7 F](#fig7){ref-type="fig"} and Fig. S4 B). Using the same criteria, we could, however, not identify a single EBF1-repressed target gene in FO B cells. In addition, EBF1 indirectly activated 10 genes by a factor of \>5 ([Fig. 7 G](#fig7){ref-type="fig"}) and indirectly repressed 10 genes by a factor of \>4 ([Fig. 7 H](#fig7){ref-type="fig"}), whereby these genes were further selected for an expression level of \>10 RPKM in WT FO B cells (activated genes) or *Ebf1*^Δ/--^ FO B cells (repressed genes). The differential expression of the *Cr2* (CD21) and *Spn* (CD43) genes was furthermore confirmed by flow cytometric analysis of control and *Ebf1*^Δ/--^ mature B cells ([Fig. 3 E](#fig3){ref-type="fig"}). Importantly, the EBF1-activated genes code for cell surface and adhesion receptors (Slamf7, Cr2; Plaur, Sema7a, and Mrgpre), signal transducers (Pik3c2b, Hck; Dusp2, Sipa1, Eps8l, and Itpr1), and transcription factors (Ell3, Egr3, Hes1, and Hopx) that have been implicated in different B cell signaling pathways ([Fig. 7, F and G](#fig7){ref-type="fig"}; see Discussion).

Ectopic EBF1 expression promotes differentiation of B-1 cells at the expense of B-2 cells
-----------------------------------------------------------------------------------------

We next performed gain-of-function experiments to further investigate the role of EBF1 in late B cell development. Although ectopic expression of EBF1 from the *R26CA*^Ebf1^ allele strongly impaired T lymphopoiesis in the thymus of *Vav*-Cre *R26CA*^Ebf1/+^ mice (unpublished data), similar to retroviral EBF1 expression ([@bib78]), it did not appear to affect B cell development in the bone marrow of *Vav*-Cre *R26CA*^Ebf1/+^ or *Cd79a*-Cre *R26CA*^Ebf1/+^ mice (unpublished data). However, B-1 cells (CD19^+^B220^lo/--^) were strongly increased at the expense of B-2 cells (CD19^+^B220^+^) in the spleen, lymph nodes, and peritoneum and, to a lower degree, in the bone marrow of *Cd79a*-Cre *R26CA*^Ebf1/+^ and *Cd23*-Cre *R26CA*^Ebf1/+^ mice in contrast to control *R26CA*^Ebf1/+^ mice ([Fig. 8, A and B](#fig8){ref-type="fig"}). This increase in B-1 cells was more pronounced upon activation of the *R26CA*^Ebf1^ allele with the earlier deletion *Cd79a*-Cre line compared with the later deletion *Cd23*-Cre line, which likely induced Cre-mediated deletion only transiently in transitional CD23^+^ B cells during B-1 cell differentiation ([Fig. 8, A and B](#fig8){ref-type="fig"}). Comparison by flow cytometric analysis indicated that the CD19^+^B220^lo/--^ B-1 cells in the spleen of *Cd79a*-Cre *R26CA*^Ebf1/+^ mice were proliferating according to their larger cell size, exhibited the classical B-1 cell surface phenotype (CD43^+^IgM^hi^IgD^lo^CD21^lo^CD23^lo/--^Mac1^--^), and consisted predominantly of CD5^+^ B-1a cells (83%) with a smaller contribution of CD5^--^ B-1b cells (9.5%), which is similar to the splenic B-1 cells of control *R26CA*^Ebf1^ littermates ([Fig. 8, C and D](#fig8){ref-type="fig"}). Moreover, the B-1a and B-1b cells in the peritoneum of both *Cd79a*-Cre *R26CA*^Ebf1/+^ and control *R26CA*^Ebf1^ mice were also comparable with regard to their proliferation rate and cell surface phenotype (unpublished data) and, in contrast to the splenic B-1 cells, they also expressed the myeloid marker Mac1, as previously described ([@bib6]).

![**Increased B-1 and reduced B-2 cell differentiation upon ectopic EBF1 expression.** (A and B) B-1 (CD19^+^B220^lo/--^) and B-2 (CD19^+^B220^+^) cells were analyzed by flow cytometry in the bone marrow, spleen, lymph nodes, and peritoneum of *R26CA*^Ebf1/+^ (white bars), *Cd79a*-Cre *R26CA*^Ebf1/+^ (gray bars), and *Cd23*-Cre *R26CA*^Ebf1/+^ (black bar) mice (A). Absolute cell numbers were determined for B-1 and B-2 cells in the bone marrow, spleen, and lymph nodes (B). *n*, number of mice analyzed. (C) Cell surface phenotype of B-1 and B-2 cells from the spleen of *R26CA*^Ebf1/+^ mice (black line) and *Cd79a*-Cre *R26CA*^Ebf1/+^ (gray) littermates. The B-1a (CD5^+^) and B-1b (CD5^--^) B cells are indicated. (D) Flow cytometric identification of B-1a cells (CD5^+^CD43^+^CD19^+^B220^lo/--^) and B-1b cells (CD5^--^CD43^+^CD19^+^B220^lo/--^) in the spleen of *Cd79a*-Cre *R26CA*^Ebf1/+^ and control *R26CA*^Ebf1/+^ littermates. The relative percentage of each B1 cell type is shown in the respective quadrant. (E--H) The relative percentages and absolute numbers of MZ and FO B cells (E and G), as well as GC B cells (F and H) were determined by flow cytometric analysis of the spleen from mice of the indicated genotypes. GC B cells were analyzed 7 d after immunization with SRBCs. Statistical data (B, G, and H) are shown with SEM and were analyzed by Student's *t* test. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; and \*\*\*\*, P \< 0.0001.](JEM_20112422R_Fig8){#fig8}

In contrast to the B-1 cells, the FO and MZ B cell numbers were reduced by 30 and 50%, respectively, in the spleen of *Cd79a*-Cre *R26CA*^Ebf1/+^ mice compared with control *R26CA*^Ebf1/+^ littermates ([Fig. 8, E and G](#fig8){ref-type="fig"}). Moreover, mature B cells from the lymph nodes of both genotypes gave rise to identical calcium mobilization in response to BCR stimulation, suggesting that BCR signaling was not affected by ectopic EBF1 expression (unpublished data). Surprisingly, GC B cells were decreased by fivefold, and thus more strongly reduced in the spleen of *Cd23*-Cre *R26CA*^Ebf1/+^ mice compared with control *R26CA*^Ebf1/+^ mice at day 7 after immunization with sheep red blood cells ([Fig. 8, F and H](#fig8){ref-type="fig"}), which was confirmed by immunohistochemical analysis (unpublished data). Hence, both ectopic EBF1 expression and EBF1 loss resulted in impaired MZ, FO, and GC B cell development, quite in contrast to the observed opposite effects of these genetic manipulations on B-1 cell differentiation. In summary, we conclude that ectopic EBF1 expression promotes the differentiation of B-1 cells at the expense of mature B-2 cell types.

Normal gene expression and V~H~ gene usage in EBF1-induced B-1 cells
--------------------------------------------------------------------

To further characterize the EBF1-induced B-1 cells, we defined the gene expression signatures characteristic of splenic B-1a and FO B cells. To this end, we compared the expression profiles of sorted WT B-1a and FO B cells (Fig. S5 A) by RNA sequencing. As shown by scatter plot analysis ([Fig. 9 A](#fig9){ref-type="fig"}), 238 genes (blue) were significantly up-regulated in splenic B-1a cells, whereas 114 genes (red) were significantly up-regulated in FO B cells. In contrast, only three significant gene expression changes could be detected by comparing WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ B-1a or FO B cells ([Fig. 9, B and C](#fig9){ref-type="fig"}; and Fig. S5 B). Importantly, the analysis of individual B-1a cell-enriched transcripts revealed that they were highly expressed in both WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ B-1a cells in contrast to their low expression in FO B cells of both genotypes ([Fig. 9 D](#fig9){ref-type="fig"}). An inverse picture was observed for FO B cell--enriched transcripts, which were highly expressed in WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ FO B cells, but not in B-1a cells of either genotype ([Fig. 9 E](#fig9){ref-type="fig"}). Hence, ectopic EBF1 expression minimally affected gene expression in both B-1a and FO B cells.

![**RNA-sequencing identified the EBF1-induced B-1a cells as bona fide B-1a cells.** (A--C) Scatter plots of gene expression differences between WT and EBF1-overexpressing B-1a and FO B cells. Two independent RNA-sequencing experiments ([Table S2](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp9}) were performed for each FACS-sorted B-1a or FO B cell type isolated from the spleen of WT or *Cd79a*-Cre *R26CA*^Ebf1/+^ mice (sorting strategy in [Fig. S5, A and B](http://www.jem.org/cgi/content/full/jem.20112422/DC1){#supp10}). The average of the normalized expression values (RPM) for each gene were plotted to indicate the gene expression differences between the different cell types. Genes are highlighted in blue or red if they were called as differentially expressed genes with an adjusted p-value of \<0.1. (D and E) Expression of B-1a cell--enriched (D) and FO B cell--enriched (E) transcripts, which were identified by comparison of WT B-1a and FO B cells (A). The expression of the indicated genes in B-1a and FO B cells of WT (gray bars) and *Cd79a*-Cre *R26CA*^Ebf1/+^ (black bars) mice is shown as average of the normalized expression value (RPKM) together with the SEM.](JEM_20112422R_Fig9){#fig9}

The B-1 cells differ from B-2 cells in their antigen specificity, as they express antibodies that weakly recognize self-antigens, including plasma membrane phospholipids such as phosphatidylcholine ([@bib6]; [@bib5]). In particular, phosphatidylcholine-binding B-1 cells predominantly express one of two immunoglobulin heavy- and light-chain combinations encoded by either the V~H~11 and V~κ~9 or V~H~12 and V~κ~4 gene segments, which determine the antibody specificity for phosphatidylcholine ([@bib55]; [@bib22]; [@bib64]). To analyze the V~H~ gene repertoire in splenic B-1a and FO B cells, we mapped, by RNA sequencing, the transcripts of functionally rearranged V~H~DJ~H~ genes to the *Igh* locus in B-1a and FO B cells of WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ mice. As shown in [Fig. 10](#fig10){ref-type="fig"}, the C~μ~ gene segments in the proximal *Igh* region were similarly transcribed in B-1a and FO B cells of both genotypes. In contrast, the expressed V~H~ sequences of the rearranged V~H~DJ~H~ genes were skewed toward the use of the V~H~11.2.53 and V~H~12.1.78 gene segments ([@bib29]) in B-1a cells of WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ mice, whereas these two V~H~ genes were not expressed in FO B cells of either genotype ([Fig. 10](#fig10){ref-type="fig"}). Similar analysis of V~κ~ gene expression identified the V~κ~4-91 and V~κ~9-128 genes ([@bib8]) to be uniquely expressed in B-1a cells of both WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ mice in contrast to FO B cells (unpublished data). Consequently, the EBF1-induced B-1a cells generated phosphatidylcholine-specific antibodies at a similar frequency compared with WT B-1a cells. Hence, the comparable V~H~ and V~κ~ gene usage and similar gene expression pattern of WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ B-1a cells unequivocally demonstrates that ectopic EBF1 expression induces the generation of bona fide B-1a cells.

![**Normal V~H~ gene repertoire in EBF1-induced B-1a cells.** Analysis of the rearranged and expressed V~H~ gene repertoire of B-1a and FO B cells by RNA-sequencing. The abundance of the 76-nt-long sequence reads, which correspond to the RNA transcripts mapping to the variable (V~H~), diversity (D~H~), joining (J~H~), and constant (C~H~) gene segments of the *Igh* locus, are shown for B-1a and FO B cells of WT and *Cd79a*-Cre *R26CA*^Ebf1/+^ mice. A schematic diagram of the *Igh* locus based on the C57BL/6 V~H~ gene assembly ([@bib29]) indicates members of the distinct V~H~ gene families in different colors. Arrows denote the positions of the V~H~11.2.53 and V~H~12.1.78 gene segments.](JEM_20112422_Fig10){#fig10}

DISCUSSION
==========

The transcription factor EBF1, like Pax5, is exclusively expressed from early B cell progenitors to mature B cells in the B lymphoid lineage of the hematopoietic system, and yet its function has so far only been explored at the initiation of B lymphopoiesis. In this study, we have uncovered novel important functions of EBF1 in early and late B cell development by performing conditional gain- and loss-of-function experiments. EBF1 is first expressed in BLPs at the onset of B cell development ([@bib27]; this study), activates *Pax5* transcription by binding to the *Pax5* promoter region ([@bib15]), and then participates in a positive cross-regulatory loop with Pax5 to maintain each other's expression at the pro--B cell stage ([@bib19]; [@bib58]). By expressing Pax5 and EBF1 independently of this feedback loop, we have now shown that ectopic Pax5 expression from the *Ikaros* locus is unable to rescue the *Ebf1* mutant phenotype at the start of B lymphopoiesis and that EBF1 expression from the *Rosa26* locus cannot overcome the Pax5 deficiency in vivo. These data therefore demonstrate that EBF1 and Pax5 fulfill nonredundant functions during B cell commitment in vivo, despite the fact that both transcription factors often bind to the same regulatory elements of common target genes in pro--B cells ([@bib35]; [@bib73]; unpublished data). EBF1 is furthermore essential for maintaining pro--B cell development and promoting the transitions to pre--B cells, as pro--B cells were reduced and pre--B cells were lost upon *Ebf1* inactivation with the early deleting *Cd79a*-Cre line. The strict EBF1 dependence of pro--B cell development and pre--BCR signaling is best explained by the multitude of activated EBF1 target genes that code for essential signaling molecules including the surrogate light chains λ5 and VpreB1/2 and the signal-transducing proteins Igα and Igβ ([@bib73]).

In mature B cells, *Ebf1* and *Pax5* are regulated independently of each other, as *Ebf1* is normally transcribed in *Pax5* mutant FO B cells (unpublished data), whereas Pax5 is normally expressed in EBF1-deficient FO B cells (this study). Although FO B cells are reduced by 40% upon conditional *Ebf1* inactivation with the late deleting *Cd23*-Cre line, the remaining FO B cells tolerate the loss of EBF1 for some time. Similarly, GC B cells in the absence of EBF1 are initially formed, but are later lost during the immune reaction, indicating that EBF1 is required for maintaining the GC B cell and plasma cell responses to foreign antigen. Interestingly, EBF1 indirectly activates the *Cr2* gene, coding for the complement receptor CD21, in mature B cells. Notably, GC B cell development and B cell responses to T cell--dependent antigens are severely impaired in *Cr2* mutant mice ([@bib1]; [@bib43]), as the survival of GC B cells is critically dependent on the expression of CD21 ([@bib17]). Hence, the strong down-regulation of CD21 expression in EBF1-deficient FO B cells may partly explain the loss of GC B cells and impaired immune responses in *Cd79a*-Cre *Ebf1*^fl/--^ mice. The transmembrane proteins CD21 and CD19 form a co-stimulatory receptor complex on mature B cells that cooperates with the BCR to efficiently bind and respond to complement C3d-fixed antigens ([@bib16]). Although CD21 recognizes the complement fragment C3d, CD19 functions as the signaling molecule of the complex to recruit Vav, PI3K, and phospholipase Cγ2 (PLCγ2) to the plasma membrane, which leads to increased calcium signaling and cell survival in response to BCR stimulation ([@bib74]; [@bib49]; [@bib11]; [@bib56]; [@bib9]). Intracellular calcium mobilization, cell survival, and proliferation are strongly reduced in EBF1-deficient FO B cells upon BCR activation, which may reflect impaired co-stimulation by the CD19--CD21 complex caused by the down-regulation of CD21 expression in the absence of EBF1. Interestingly, EBF1 directly activates the expression of the type 1 IP~3~ receptor (Itpr1), which functions as an intracellular calcium release channel in response to the second messenger inositol 1,4,5-trisphosphate (IP~3~; [@bib60]). Hence, the reduced expression of *Itpr1* is likely to contribute to the calcium signaling defect of EBF1-deficient FO B cells.

Genome-wide analysis of EBF binding unexpectedly revealed only 281 EBF1 peaks and 247 EBF1 target genes in FO B cells, although the EBF1 protein is expressed only at a threefold lower level in FO B cells compared with pro--B cells. As we analyzed EBF1 binding in quiescent FO B cells, it remains a possibility that EBF1 may interact with more target genes in activated B cells. However, the observed small number of EBF1 peaks is unlikely to result from technical difficulties to detect EBF1 binding, as ChIP-sequencing with the same EBF1 antibody identified 5,071 peaks corresponding to 3,321 EBF1 target genes in pro--B cells, similar to recently published results obtained by ChIP-sequencing of A-MuLV-transformed pro--B cells ([@bib73]). In contrast to EBF1, Pax5 binds to 15,468 genomic sites in mature cells (unpublished data), which results in the colocalization of Pax5 peaks with two-thirds (184) of all EBF1-binding sites in FO B cells. Surprisingly, EBF1 efficiently activates only 10 (4%) of its target genes in FO B cells. One of these target genes, *Ell3*, is commonly activated in pro--B and mature B cells, and yet the other activated target genes are also already bound by EBF1 in pro--B cells, suggesting that transcription factors expressed in late B cell development cooperate with EBF1 to regulate these genes specifically in FO B cells ([@bib73]; this study). EBF1 directly activates a single transcription factor gene coding for Egr3, which has been implicated in the control of T cell proliferation and survival in response to (pre)TCR signaling ([@bib75]; [@bib59]; [@bib12]). As *Egr3* is only threefold activated by EBF1 in FO B cells, it is unlikely able to mediate the much stronger indirect regulation of several EBF1-dependent genes. In contrast, the direct target gene *Ell3* is 36-fold down-regulated in the absence of EBF1 and codes for a transcription elongation factor and component of the super-elongation complex (SEC), which controls the release of promoter-proximal stalled RNA polymerase II into productive elongation of transcription ([@bib42]; [@bib68]). It is thus conceivable that the near loss of Ell3 may interfere with the transcription elongation of indirectly EBF1-activated genes.

Compared with *Cr2*, other EBF1-activated genes coding for cell surface receptors or signal transducers have been less well characterized with regard to their function in late B cell development. The cell surface receptor Slamf1 (CD150) is activated by homophilic Slamf1 interactions between B cells or B and T cells within lymphoid follicles, and it enhances B cell proliferation as a co-stimulatory receptor in concert with BCR or CD40 signaling by activating the PI3K and MAPK pathways ([@bib54]; [@bib41]; [@bib76]). The Src family kinase Hck has been implicated in cell proliferation in response to IL-6 signaling ([@bib52]), whereas the phosphatase Dusp2 negatively regulates BCR-mediated cell proliferation by dephosphorylating the MAP kinase Erk2 upon co-ligation of the BCR and low-affinity IgG receptor FcγRIIb by IgG-containing immune complexes ([@bib10]; [@bib79]). The GTPase-activating protein Sipa1 promotes signaling from the small G protein Rap1, which has been implicated in B-1a cell development by controlling the generation of the skewed Vκ gene repertoire ([@bib28]), and in lymphocyte adhesion and trafficking by enhancing integrin function ([@bib30]; [@bib62]). The GPI-anchored urokinase receptor Plaur is also involved in signaling lymphocyte adhesion, migration, and proliferation during immune responses, in addition to its proteolytic activation of the urokinase plasminogen activator (uPA) leading to extracellular matrix degradation ([@bib7]). The cell surface protein semaphorin 7A (Sema7a) is known for its important function in T cell--mediated inflammatory responses, as its expression on activated T cells promotes integrin α1β1 binding and recruitment of macrophages to sites of inflammation ([@bib70]). The PI3K C2β (Pik3c2b) is a member of the poorly characterized class II PI3K family and has been implicated in cell migration by associating with the trimeric Eps8--Abi--Sos1 complex, which functions as a guanine nucleotide exchange factor to activate the small G protein Rac, leading to actin cytoskeleton remodeling ([@bib36]; [@bib31]). Finally, the adaptor molecule Eps8L1 interacts with the signaling chain CD3ε of the TCR ([@bib32]) and, like its related protein Eps8, promotes actin reorganization by controlling the activity of Rac ([@bib50]). Although the function of some of the EBF1-activated genes in mature B cells remains to be investigated, their role in the related T cell lineage suggests that the reduced expression of these genes in response to EBF1 loss also contributes to the *Ebf* mutant phenotype in late B cell development.

EBF1 is particularly important for the generation of B-1 and MZ B cells, as these two innate-like mature B cell types do not tolerate the loss of EBF1. Although B-1 cells are predominantly located in peritoneal and pleural cavities and MZ B cells in the antigen-filtrating MZ of the spleen, they share similar properties and constitute the first line of defense against blood-borne microorganisms by rapidly differentiating into short-lived plasma cells ([@bib38]; [@bib23]; [@bib5]). B-1 and MZ B cells have self-renewal potential and express a selected BCR repertoire recognizing bacterial cell wall constituents and self-antigens such as phospholipids ([@bib21]; [@bib38]; [@bib5]; [@bib44]). Although the loss of B-1 and MZ B cells upon conditional *Ebf1* inactivation precludes the identification of regulated EBF1 target genes in these two cell types, it is worth noting that B-1a cells are reduced in *Cr2* (CD21)-null mice ([@bib1]), which is consistent with the idea that strong autoantigen-driven BCR signaling is required for the maturation and self-renewal of B-1a cells ([@bib13]; [@bib5]; [@bib44]). In this context, it is important to emphasize that the loss of B-1 cells upon *Ebf1* mutation may be best explained by the impaired proliferation of EBF1-deficient mature B cells in response to BCR stimulation.

Furthermore, we have shown that ectopic expression of EBF1 from the *Rosa26* locus efficiently induces the development of B-1 cells at the expense of MZ and FO B cells. Importantly, the EBF1-induced B-1a cells exhibit the same gene expression signature and preference for immunoglobulin rearrangements, creating phosphatidylcholine-specific antibodies, as WT B-1a cells, which identifies EBF1 as the first transcription factor capable of diverting conventional B cells in the B-1 cell fate. The B-1 cell lineage is thought to develop from B-1 cell--specific progenitors in early B lymphopoiesis ([@bib45]). In agreement with this idea, B-1 cell development is most efficiently induced if EBF1 expression from the *Rosa26* locus is activated by early deletion with the *Cd79a*-Cre line. However, activation of EBF1 expression by the *Cd23*-Cre line, which initiates Cre expression only in CD23^+^ transitional B cells of the spleen ([@bib33]), is still able to generate B-1 cells at an advanced stage of B cell development. This latter finding is more in line with the activation-induced model postulating that B-1 cells develop in response to the recognition of certain self-antigens and common bacterial cell wall constituents by the BCR ([@bib6]). It remains to be seen whether the EBF1-induced B-1 cells originate predominantly in fetal B lymphopoiesis, like most B-1 cells of WT mice ([@bib44]). Investigating the developmental timing and critical EBF1 target genes involved in the B-2 to B-1 lineage diversion are interesting and challenging questions for future studies.

MATERIALS AND METHODS
=====================

### Mice.

The following mice were maintained on the C57BL/6 genetic background: *Ebf1*^+/−^ ([@bib34]), *Pax5*^fl/fl^ ([@bib25]), *Ikzf1*^Pax5/+^ ([@bib69]), *Cd79a*^Cre/+^ ([@bib24]), *Mox2*^Cre/+^ ([@bib71]), transgenic *Vav*-Cre ([@bib14]), transgenic *Cd23*-Cre ([@bib33]), and transgenic FLPe ([@bib57]) mice. Throughout this article, the heterozygous *Cd79a*^Cre/+^ genotype is referred to as *Cd79a*-Cre (also known as *mb1*-Cre; [@bib24]). All animal experiments were performed according to valid project licenses, which were approved and regularly controlled by the Austrian Veterinary Authorities.

### Generation of the *Ebf1*^ihCd2^ allele.

The targeting vector for generating the *Ebf1*^ihCd2^ allele was obtained by first inserting the following sequences in the 5′ to 3′ direction (Fig. S1 A) into the *Ebf1* bacterial artificial chromosome (BAC) RP23-14018 by recombineering in *Escherichia coli*: 233-bp MfeI--AscI fragment containing C-terminal tag sequences (fused in frame to the last *Ebf1* codon), 1.8-kb AscI--SalI fragment containing the IRES-*hCd2* (ihCd2) reporter gene (flanked by *frt* sites), and 1.9-kb SalI--XhoI fragment containing the mouse phosphoglycerate kinase promoter linked to the neomycin resistance gene (flanked by *loxP* sites). The tag sequences contained cleavage sites for the PreScission (PreSc) and TEV proteases, epitopes for Flag and V5 antibodies, and a biotin acceptor sequence (Biotin) for biotinylation by the *E. coli* biotin ligase BirA. In a second step, the *Ebf1*^ihCd2^ targeting vector was generated by excising and inserting the integrated sequences together with the flanking 5′ (1.9 kb) and 3′ (5.0 kb) homology regions by recombineering from the modified BAC into the pBV-DTA-pA plasmid containing an *HSV-TK* gene (for negative selection). 15 µg SgrA1-linearized DNA was electroporated into cells (10^7^) of the hybrid C57BL/6 × 129^SV^ ES cell line A9, followed by selection with 250 µg/ml G418. PCR-positive clones were verified by Southern blot analysis of BamHI-digested DNA (Fig. S1 B) before injection into C57BL/6 blastocysts and the generation of *Ebf1*^ihCd2−Neo/+^ mice. The *Ebf1*^ihCd2^ allele was obtained by crossing *Ebf1*^ihCd2−Neo/+^ mice with the *Mox2*-Cre line ([@bib71]). The following primers were used for PCR genotyping of *Ebf1*^ihCd2/+^ mice: (a) 5′-TCTCACTATTTTGCAAAGTCTGAGG-3′; (b) 5′-GGGCTTGCTTTTTATCAATACAGA-3′; and (c) 5′-TTGTAGTCAGGTCCCTGGAACA-3′. The WT *Ebf1* allele was identified as a 624-bp PCR fragment with the primer pair a/b, and the *Ebf1*^ihCd2^ allele as a 410-bp PCR fragment with the primer pair a/c (Fig. S1 C).

### Generation of the floxed *Ebf1* allele.

The conditional *Ebf1* targeting vector was assembled in the pBV-DTA-pA plasmid containing an *HSV-TK* gene (for negative selection), as well as a polylinker with appropriate restriction sites for insertion of the following sequences in the 5′ to 3′ direction (Fig. S2 A): a 5.0-kb NotI--AscI fragment (cloned as long 5′ homology region from BAC RP23-82015 by recombineering in *E. coli*); a *loxP* site present in the polylinker; a 3.2-kb XhoI--SalI fragment (containing the 3′ end of *Ebf1* intron 5, exon 6 fused in frame to *Ebf1* cDNA sequences from exon 7 to the 3′ untranslated region, 6 copies of the SV40 polyA region and a second *loxP* site); a 1.7-kb SalI--RsrII fragment (containing the 3′ end of *Ebf1* intron 5 and the first 14 codons of exon 6 linked in frame to a *Gfp* gene, polyadenylation signal, *frt* site, and the 3′ end of the neomycin \[Neo\] resistance gene \[in opposite orientation to *Ebf1*\]); 1.35-kb RsrII--ClaI fragment (containing the middle and 5′ end sequences of the Neo gene, the mouse phosphoglycerate kinase promoter, and the second *frt* site); and a 1.9-kb ClaI--BsiWI fragment (cloned as short 3′ homology region from BAC RP23-82015 by recombineering). 15 µg SgrA1-linearized DNA was electroporated into cells (10^7^) of the hybrid C57BL/6 × 129^SV^ ES cell line A9, followed by selection with 250 µg/ml G418. PCR-positive clones were verified by Southern blot analysis of ApaI-digested DNA (Fig. S2 B) before injection into C57BL/6 blastocysts and the generation of *Ebf1*^fl−neo/+^ mice. The *Ebf1*^fl^ allele was obtained by crossing *Ebf1*^fl−neo/+^ mice with the FLPe line ([@bib57]) and the *Ebf1*^Δ^ allele by crossing *Ebf1*^fl/+^ mice with the *Mox2*-Cre line ([@bib71]). The following primers were used for PCR genotyping of *Ebf1*^fl/+^ mice: (a) 5′-CTGTCCCTAGGATCCGTTGA-3′; (b) 5′-AGATGGATTACGTCCAACAGAA-3′; and (c) 5′-ACACCACGACCTGGAATCTC-3′. The WT *Ebf1* allele was identified as a 647-bp PCR fragment with the primer pair a/b, and the floxed *Ebf1*^fl^ allele as a 363-bp PCR fragment with the primer pair a/c (Fig. S2 C). A second set of primers was used for simultaneous PCR genotyping of the floxed and deleted *Ebf1* alleles: (d) 5′-CCCAAATAGAGTTTTCTGTCCCTA-3′; (e) 5′-AGATGAACTTCAGGGTCAGCTTG-3′; and (f) 5′-AGGAATGACCTTCTGTAACCTCTG-3′. The floxed *Ebf1*^fl^ allele gave rise to an 800-bp PCR fragment with the primer pair d/e, and the deleted *Ebf1*^Δ^ allele to a 420-bp PCR fragment with the primer pair d/f.

### Generation of the *R26CA*^Ebf1^ allele.

Full-length *Ebf1* cDNA linked in frame to the tag sequences shown in Fig. S3 A was cloned into the AscI site of the targeting vector CAG-STOP-eGFP-ROSA26TV ([www.addgene.org](http://www.addgene.org){#supp11}). The AsiSI-linearized targeting vector was electroporated into cells (10^7^) of the hybrid C57BL/6 × 129^SV^ ES cell line A9, followed by selection with 250 µg/ml G418. Targeted ES cell clones were identified by Southern blot analysis (Fig. S3 B). The following primers were used for PCR genotyping of *R26CA*^Ebf1/+^ mice: (a) 5′-AAGGGAGCTGCAGTGGAGTA-3′; (b) 5′-TAAGCCTGCCCAGAAGACTC-3′; and (c) 5′-CGCCGCCGGGATCACTCTCG-3′. The WT *Rosa26* (*R26*) allele was identified as a 209-bp PCR fragment with primers a/b, and the *R26CA*^Ebf1^ allele as a 508-bp PCR fragment with primers c/b.

### Flow cytometry.

Mice at 4--5 or 6--10 wk of age were used for FACS analyses of lymphoid progenitors and mature B cell types, respectively. Single-cell suspensions of bone marrow, spleen, and lymph nodes were incubated with CD16/CD32 Fc block (BD) to inhibit unspecific antibody binding. For flow cytometry, cells were stained with the following antibodies: anti-B220/CD45R (RA3-6B2), CD3ε (145-2C11), CD4 (GK1.5), CD8a (53--6.7), CD5 (53--7.3), CD11b/Mac1 (M1/70), CD11c (HL3), CD19 (1D3), CD20 (AISB12), CD21/CD35 (7G6), CD22 (Cy34.1), CD23 (B3B4), CD24/HSA (M1/69), CD25/IL-2Rα (PC61), CD28 (37.51), CD38 (90), CD40 (3/23), CD43 (S7), CD44 (IM781), CD49b (DX5), CD86 (GL1), CD93/AA4.1 (PB493), CD95/Fas (Jo2), CD117/c-Kit (ACK4), CD127/IL-7Rα (A7R34), CD135/Flt3 (A2F10.1), CD138 (281--2), F4/80 (CI:A3-1), Gr1 (RB6-8C5), MHCII (M5-114), IgD (1.19), IgG1 (A85-1), IgG3 (R40-82), IgM (M41.42), IgM^a^ (Igh-6a/DS-1), IgM^b^ (AF6-78), NK1.1 (PK136), Ly5.1 (A20), Ly5.2 (104), Ly6C (6C3), Ly6D (49H4.3), Sca1/Ly6A (D7), TCRβ (H57-597), Ter119 (TER119), Thy1.2 (53--2.1), and human CD2 (RPA-2.10) antibodies.

### FACS sorting and definition of hematopoietic cell types.

The different hematopoietic cell types were identified by flow cytometry or sorted with a FACSAria machine (BD), as follows: LSK MPPs (Lin^--^IL-7Rα^--^Sca1^hi^c-Kit^hi^), CLPs (Lin^--^IL-7Rα^+^Flt3^+^Sca1^lo^c-Kit^lo^), ALP (Ly6D^--^ CLPs), BLP (Ly6D^+^ CLPs), prepro--B (DX5^--^Ly6C^--^CD19^--^B220^+^c-Kit^+^), pro--B (CD19^+^c-Kit^+^CD25^--^IgM^--^IgD^--^), pre--B (CD19^+^CD25^+^c-Kit^--^IgM^--^IgD^--^), immature B (CD19^+^IgM^hi^IgD^lo^CD93^+^), mature B (CD19^+^ IgM^lo^ IgD^hi^ CD93^--^), MZ B (CD19^+^CD21^hi^CD23^lo/--^), FO B (CD19^+^CD21^int^CD23^hi^), GC B (CD19^+^PNA^+^Fas^+^), B-1 cells (CD19^+^B220^lo/--^), plasma cells (Lin^--^CD138^hi^CD28^+^), total B cells (CD19^+^B220^+^), and granulocytes (Gr1^+^Mac1^+^). Lineage-positive (Lin^+^) cells were MACS depleted, and then electronically gated away with the following lineage marker antibodies: B220, CD19, CD4, CD8a, TCRβ, DX5, Gr1, Ly6C, Mac1, CD11c, and Ter119 (for MPPs, CLPs, ALPs, and BLPs); and CD4, CD8a, CD21, and F4/80 (for plasma cells). WT mature B cells were purified for ChIP-seq experiments from lymph nodes by MACS depletion of non--B cells with anti-PE beads after staining with PE-labeled TCRβ, CD4, CD8a, Mac1, Gr1, DX5, and Ly6C antibodies. For RNA sequencing, FO B cells were FACS sorted as B220^+^CD19^+^CD21^lo/--^CD23^+^IgM^lo^IgD^hi^ cells and B-1a cells as CD19^+^B220^lo/--^CD5^+^ cells from the spleen (Fig. S5).

### Competitive bone marrow transplantation.

Bone marrow cells from *Cd23*-Cre mice (Ly5.2) and *Cd23*-Cre *Ebf1*^fl/fl^ mice (Ly5.2) were twice depleted of T cells by MACS depletion with TCRβ, CD4, and CD8a antibodies, and then each mixed at a 1:1 ratio with bone marrow cells from WT mice (C57BL/6-Ly5.1) before intravenous injection into C57BL/6-Ly5.1 mice, which were γ-irradiated with a single dose of 12 Gy 24 h before. Peripheral blood was analyzed by flow cytometry 10 wk after bone marrow transplantation.

### Calcium fluorometry.

FO B cells (2 × 10^6^) were isolated from lymph nodes by MACS depletion of non--B cells with anti-PE beads after staining with PE-labeled TCRβ, CD4, CD8a, Mac1, and DX5 antibodies. Purified B cells (2 × 10^6^) were loaded with indo-1 acetoxymethylester (Invitrogen) at a final concentration of 1 µM in 1 ml of RPMI-1640 medium containing 10% fetal calf serum. After incubation at 37°C for 45 min, the cells were washed twice and reincubated at 37°C for an additional 30 min. Propidium iodide was added, and the fluorescence ratio of Indo-1 emission at 405/485 nm was measured in live cells on a LSR flow cytometer (BD). The acquisition of the data was initiated 30 s before the addition of the monoclonal anti-IgM antibody M41.42 (at 10 µg/ml). The data were collected for 180 s and analyzed using FlowJo software (Tree Star).

### In vitro B cell stimulation experiments.

Mature B cells were isolated from the lymph nodes by depletion of non--B cells or enrichment of B220^+^ B cells by MACS sorting. The purified B cells were plated at 0.5 × 10^6^ cells/ml in IMDM medium supplemented with 10% fetal calf serum, and were subsequently treated for up to 4 d with 10 µg/ml anti-IgM (M41.42) antibody alone ([Fig. 6 B](#fig6){ref-type="fig"}), with 10 µg/ml anti-IgM antibody and 20 ng/ml rIL-4 (R&D Systems; [Fig. 6 C](#fig6){ref-type="fig"}), or with 1 µg/ml anti-CD40 antibody (HM-40-3; eBioscience) and 20 ng/ml rIL-4 ([Fig. 6, C and D](#fig6){ref-type="fig"}). For cell proliferation analysis, the purified B cells were first stained with 5 µM CellTrace Violet reagent (Invitrogen) before stimulation, as described above.

### Immunizations and plasma cell analysis.

SRBCs were washed in PBS and resuspended at 10^9^ cells/ml, followed by intraperitoneal injection of 100 µl into an adult mouse. The immune response to a specific antigen was studied by intraperitoneal injection of 100 µg of 4-hydroxy-3-nitrophenylacetyl--conjugated keyhole limpet hemocyanin (in Alum). The frequencies of anti--NP-IgG1 ASCs were determined in the spleen and bone marrow by ELISpot assay as previously described ([@bib66]). NP~4~-BSA-- and NP~23~-BSA--coated plates were used for capturing high-affinity or total anti--NP-IgG1 antibodies secreted by individual cells, respectively. Spots were visualized with goat anti--mouse IgG1 antibodies conjugated to alkaline phosphatase (SouthernBiotech), and color was developed by the addition of BCIP/NBT Plus solution (SouthernBiotech). After extensive washing, the spots were counted with an AID ELISpot reader system (AID Diagnostika).

The serum titer of NP-specific IgG1 antibodies was determined by ELISA ([@bib66]) by using plates that were coated with 25 µg/ml of NP~4~-BSA or NP~23~-BSA to capture high-affinity or total NP-specific IgG1 antibodies, respectively. The serum concentration of NP-specific IgG1 was determined relative to that of a standard anti-NP IgG1 antibody (hybridoma SSX2.1).

### Histological analysis.

Cryosections of the spleen from immunized mice were stained with a FITC-anti-IgD antibody (11-26c.2a; BD) and biotinylated PNA (B-1075; Vector Laboratories). FITC-anti-IgD was detected with an alkaline phosphatase--coupled anti-FITC antibody (Roche) that was visualized by incubation with Fast Blue (Sigma-Aldrich). Biotinylated PNA was detected with horseradish peroxidase--conjugated streptavidin (BD), followed by incubation with DAB (Sigma-Aldrich).

### Antibodies.

A rabbit polyclonal EBF1 antibody was raised against a bacterially expressed His-tagged EBF1 polypeptide, which contained N-terminal sequences from amino acid residue 15 (Met) to residue 259 (His) of mouse EBF1 ([@bib20]), and was affinity-purified with immobilized antigen. A rabbit polyclonal Pax5 antibody (directed against the Pax5 residues 17--145) and a mouse monoclonal TATA-binding protein (TBP) antibody (clone TBP-3G3; obtained from L. Tora) were used as controls for immunoblot analysis.

### ChIP analysis of EBF1 binding.

Pro--B cells isolated from the bone marrow of *Rag2^−/−^* mice were expanded in vitro for 4--5 d on OP9 cells in the presence of IL-7, and mature FO B cell were purified from lymph nodes of WT C57BL/6 mice as described above. The *Rag2^−/−^* pro--B cells and purified FO B cells were subjected to ChIP with an EBF1 antibody (see above) as described ([@bib61]). The ChIP efficiency was controlled by real-time PCR analysis ([@bib15]) before Solexa sequencing (Illumina) of the precipitated DNA.

### cDNA preparation for RNA sequencing.

RNA was isolated from ex vivo--sorted cells using the RNeasy Plus Mini kit (QIAGEN), and mRNA was obtained by two rounds of poly(A) selection using the Dynabeads mRNA purification kit (Invitrogen) followed by fragmentation by heating at 94°C for 3 min. The fragmented mRNA was used as template for first-strand cDNA synthesis with random hexamers using the SuperScript VILO cDNA Synthesis kit (Invitrogen). dNTPs were removed on a Mini Quick Spin Column (Roche) before the second-strand cDNA synthesis with 100 mM dATP, dCTP, dGTP, and dUTP in the presence of RNase H, *E. coli* DNA polymerase I and DNA ligase (Invitrogen). The incorporation of dUTP allowed elimination of the second strand during library preparation (see below), thereby preserving strand specificity ([@bib51]).

### Solexa deep sequencing.

Approximately 5 ng of cDNA or ChIP-precipitated DNA were used as starting material for the generation of single-end sequencing libraries as described by Illumina's ChIP Sequencing sample preparation protocol. DNA fragments of 200--350 bp and 150--700 bp were selected for ChIP-seq and RNA-seq experiments, respectively. For strand-specific RNA-sequencing, the uridines present in one cDNA strand were digested with uracil-N-glycosylase (New England Biolabs) as previously described ([@bib51]), followed by PCR amplification. Completed libraries were quantified with the Agilent Bioanalyzer dsDNA 1000 assay kit and Agilent QPCR NGS library quantification kit. Cluster generation and sequencing was performed by using the Illumina/Solexa Genome Analyzer II and IIx systems according to the manufacturer's guidelines.

### Peak calling of ChIP-seq data.

Peaks were called using the MACS program version 1.3.6.1 ([@bib80]) with default parameters, a read length of 36, a genome size of 2,654,911,517 bp (mm9) and the appropriate input control sample. Peaks were filtered for p-values of \<10^−10^. This stringent cutoff efficiently removed false positive (unique) peaks of technical replicas.

### Analysis of RNA-seq data.

For analysis of differential gene expression, the RNA-seq samples were cut down to a common read length (30 bp) and aligned to the mouse transcriptome using the TopHat version 1.3.1 ([@bib72]). The number of reads per gene was counted using the HTseq version 0.5.3 (<http://www-huber.embl.de/users/anders/HTSeq>) with the overlap resolution mode option set to "union." As two independent RNA-seq experiments were available for each cell type shown in [Fig. 9 (A--C)](#fig9){ref-type="fig"}, the corresponding RNA-seq data were compared by using the R package DESeq version 1.6.1 ([@bib3]) to calculate the significance level of differential expression. To this end, the samples were normalized, and the dispersions were estimated using the default DESeq settings. Genes with an adjusted p-value of \<0.1 were called as differentially expressed.

### Accession nos.

The ChIP-seq and RNA-seq data discussed in this paper are available at the Gene Expression Omnibus (GEO) database under the accession no. [GSE35857](GSE35857).

### Online supplemental material.

Fig. S1 describes the generation of the *Ebf1*^ihCd2^ allele. Fig. S2 describes the generation of the *Ebf1*^fl^ allele. Fig. S3 describes the generation of the *R26CA*^Ebf1^ allele. Fig. S4 deals with the binding of EBF1 to it target genes in mature B cells. Fig. S5 documents the FACS sorting and reanalysis of FO and B-1a B cells used for RNA-sequencing. Table S1 shows the sequence coordinates of EBF1 peaks in FO B cells. Table S2 is a description of Solexa sequencing experiments generated for this study. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20112422/DC1>.
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